(ovarian/colorectal) NEOVACS to collaborate with the SUNNYBROOK RESEARCH INSTITUTE for preclinical development of VEGF Kinoid

press release:
NEOVACS to collaborate with the SUNNYBROOK RESEARCH INSTITUTE for preclinical development of VEGF Kinoid to treat colorectal cancer and ovarian cancer 

PRESS RELEASE

NEOVACS to collaborate

with the SUNNYBROOK RESEARCH INSTITUTE

for preclinical development of  VEGF Kinoid

to treat  colorectal cancer and ovarian cancer

Paris and Boston, January 5^th, 2017 - Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapies for the treatment of autoimmune diseases, today announced its collaboration with Professor Robert Kerbel and his team at the Sunnybrook Research Institute of Toronto, Canada for preclinical development of Neovacs' VEGF Kinoid, specifically to obtain the proof of concept for the treatment of colorectal and ovarian cancer.

The Neovacs technology presents a major new therapeutic opportunity for these types of cancers where the VEGF-A (vascular endothelial growth factor) protein plays an important role in the vascularization of the tumor. Indeed the Neovacs approach, based on active immunotherapy, aims to enhance the immune system of the patient by enabling it to produce self-polyclonal antibodies, which will selectively target and neutralize the cytokine VEGF-A. For these types of cancer the neutralization of VEGF-A could prevent tumor growth and development of metastases.

Professor Robert Kerbel, has contributed to a large number of preclinical trials and overseen numerous international clinical trials in cancer. "Our cooperation with Neovacs demonstrates the commitment of the Sunnybrook Research Institute to contribute to the development of innovative therapies in cancer. Thanks to this agreement we hope to enable patients suffering from a colorectal or ovarian cancer to benefit from an innovative and potentially very efficient therapy," said Professor Robert Kerbel......